Market Overview

The Top IPO Of 2014

The Top IPO Of 2014
Related RDUS
14 Stocks Moving In Tuesday's Pre-Market Session
15 Stocks Moving In Monday's Pre-Market Session

Now that 2014 is winding down, it's a good time to look at the best IPOs of the year. There were plenty of IPO winners this year, but only one company can lay claim to the title of best IPO of 2014.

Best IPO: Radius Health (+370%)

Despite the massive size and all the press surrounding the Alibaba Group Holding Ltd (NYSE: BABA) IPO, the honors of best IPO of 2014 go to Radius Health Inc (NASDAQ: RDUS). Radius Health, a developer of treatments for osteoporosis and other women’s heath conditions, went public back on June 9.

After IPO shares priced at $8.00, the first day of trading was relatively uneventful. IPO investors saw the stock close up just a penny to $8.01 on the stock’s first day on the market.

Related Link: The Biggest REIT Story Of 2014

However, Radius Health started gaining momentum in the weeks following the IPO, and the stock never looked back. Radius Health recently peaked as high as $42.57 last week before pulling back to its current price of $37.67. This price represents a 370 percent gain from the IPO price.

Investors that weren’t lucky enough to get in on the Radius Health IPO but acted quickly on its first day of trading have enjoyed similar gains this year.

These incredible gains are more than enough to earn Radius Health the distinction of best-performing IPO of the year 2014.

Runner Up: Auspex Pharmaceuticals (+218%)

This year’s runner up for best IPO goes to small-cap biotech stock Auspex Pharmaceuticals Inc (NASDAQ: ASPX). The company is focused on developing novel treatments for orphan diseases.

After pricing its February 5 IPO at $12.00, the high end of the projected range, Auspex stock opened for trading at $15.00 and closed its first day at $15.66.

The stock steadily climbed throughout the rest of the year, but it leaped from around $25.00 to over $50.00 a couple of weeks ago on news of positive results from a Huntington’s disease treatment study.

The current price of $49.79 represents about a 218 percent gain for IPO investors.

Investing in IPOs can be a risky game, but, as investors in these two 2014 IPOs can attest, sometimes the payoff is fast and huge.

Check back on Benzinga for the worst-performing IPO of 2014.

Posted-In: Long Ideas Top Stories Movers Trading Ideas Best of Benzinga


Related Articles (ASPX + RDUS)

View Comments and Join the Discussion!